Peer Review reports
From: HYAL3 as a potential novel marker of BLCA patient prognosis
| Original Submission | ||
|---|---|---|
| 4 Mar 2022 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| 7 Apr 2022 | Reviewed | Reviewer Report |
| 15 Apr 2022 | Reviewed | Reviewer Report |
| 24 May 2022 | Author responded | Author comments - Hao Lin |
| Resubmission - Version 3 | ||
| 24 May 2022 | Submitted | Manuscript version 3 |
| 30 May 2022 | Author responded | Author comments - Hao Lin |
| Resubmission - Version 4 | ||
| 30 May 2022 | Submitted | Manuscript version 4 |
| 2 Jun 2022 | Author responded | Author comments - Hao Lin |
| Resubmission - Version 5 | ||
| 2 Jun 2022 | Submitted | Manuscript version 5 |
| 16 Jun 2022 | Reviewed | Reviewer Report |
| 20 Jun 2022 | Reviewed | Reviewer Report |
| 4 Jul 2022 | Author responded | Author comments - Hao Lin |
| Resubmission - Version 6 | ||
| 4 Jul 2022 | Submitted | Manuscript version 6 |
| Publishing | ||
| 8 Jul 2022 | Editorially accepted | |
| 9 Aug 2022 | Article published | 10.1186/s12863-022-01070-w |
You can find further information about peer review here.